Notably, CSF PINK1 and ULK1 levels were markedly elevated in groups with more advanced pathology in both FTLD (A-T + N+) and AD (A + T + N+) compared to the groups with negative P-tau181 and T-tau (A-T-N-, A + T-N-). This evidence concerns the gene MAPT and Alzheimer disease.